

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EPS Creative Health Technology Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3860)

**(1) CHANGE OF DIRECTORS, CHAIRMAN OF THE BOARD AND
CHIEF EXECUTIVE OFFICER;
(2) CHANGE OF AUTHORISED REPRESENTATIVE; AND
(3) CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE**

The Board hereby announces the following appointments and resignations with effect from 1 November 2023:

- (1) Mr. Okoso has tendered his resignation as an executive Director, the Chairman and the Chief Executive Officer;
- (2) Mr. Gao has tendered his resignation as an executive Director, a LR Authorised Representative and a CO Authorised Representative;
- (3) Mr. Xia has tendered his resignation as a non-executive Director;
- (4) Mr. Shimada has been appointed as an executive Director, the Chairman and the Chief Executive Officer;
- (5) Mr. Miyazato has been appointed as an executive Director and the Chief Strategy Officer;
- (6) Mr. Chiu has been appointed as an executive Director;
- (7) Each of Mr. Kusaba and Mr. Yan has been appointed as a non-executive Director;
- (8) Mr. Saito has been appointed as an independent non-executive Director; and
- (9) Mr. Miyano has been appointed as a LR Authorised Representative.

RESIGNATION OF EXECUTIVE DIRECTORS, NON-EXECUTIVE DIRECTOR, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE OFFICER AND AUTHORISED REPRESENTATIVES

The board (the “**Board**”) of directors (the “**Directors**”) of EPS Creative Health Technology Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Okoso Satoshi (“**Mr. Okoso**”) has tendered his resignation as (i) an executive Director, (ii) the chairman of the Board (the “**Chairman**”); and (iii) the chief executive officer of the Company (the “**Chief Executive Officer**”), all with effect from 1 November 2023 in order to focus on his personal and other business engagements.

Mr. Gao Feng (“**Mr. Gao**”) has tendered his resignation as (i) an executive Director; (ii) an authorised representative of the Company (the “**LR Authorised Representative**”) under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”); (iii) an authorised representative (the “**CO Authorised Representative**”) under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong); and (iv) the chief strategy officer of the Company (the “**Chief Strategy Officer**”), all with effect from 1 November 2023 in order to devote more time to his personal and other business commitments.

Mr. Xia Xiangming (“**Mr. Xia**”) has tendered his resignation as a non-executive Director and a member of the audit committee of the Board (the “**Audit Committee**”) with effect from 1 November 2023 in order to focus on his personal and other business engagements.

Each of Mr. Okoso, Mr. Gao and Mr. Xia has confirmed that he has no disagreement with the Board and that he is not aware of any other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

The Board would like to take this opportunity to express its gratitude to Mr. Okoso, Mr. Gao and Mr. Xia for their valuable efforts and contributions to the Company during their tenure of office with the Company.

APPOINTMENT OF EXECUTIVE DIRECTORS, CHAIRMAN OF THE BOARD, CHIEF EXECUTIVE OFFICER, NON-EXECUTIVE DIRECTORS AND INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that with effect from 1 November 2023, (i) Mr. Shimada Tatsuji (“**Mr. Shimada**”) has been appointed as an executive Director, the Chairman and the Chief Executive Officer; (ii) Mr. Miyazato Hiroki (“**Mr. Miyazato**”) has been appointed as an executive Director and the Chief Strategy Officer; (iii) Mr. Chiu Chung Tak (“**Mr. Chiu**”) has been appointed as an executive Director; (iv) each of Mr. Kusaba Takuya (“**Mr. Kusaba**”) and Mr. Yan Ping (“**Mr. Yan**”) has been appointed as a non-executive Director; and (v) Mr. Saito Hironobu (“**Mr. Saito**”) has been appointed as an independent non-executive Director.

Set out below are the biographical details of the new Directors:

Executive Directors

Mr. Shimada, aged 62, is the Managing Corporate Officer of EPS Holdings, Inc. (“**EPS Japan**”), which is a controlling shareholder (as defined under the Listing Rules) of the Company. Mr. Shimada joined EPS Japan in October 2018 and has over 39 years of experience in pharmaceutical business. Prior to joining EPS Japan, Mr. Shimada worked in Chugai Pharmaceutical Co., Ltd., a Japanese pharmaceutical company the shares of which are listed on the Japanese (Tokyo) Stock Exchange (ticker code: 4519), from 1984 to 2018 in which he had been the chief executive officer of Chugai Pharma Taiwan Ltd. and the International Marketing Manager of Chugai-Rhone-Poulenc SA, Paris France. Mr. Shimada is a colleague of Mr. Miyano Tsumoru (“**Mr. Miyano**”), Mr. Haribayashi Keikyo (“**Mr. Hari**”), Mr. Maezaki Masahiro (“**Mr. Maezaki**”), the existing executive Directors, and Mr. Kusaba, a newly appointed non-executive Director, in EPS Japan.

Mr. Shimada graduated from Waseda University in Tokyo, Japan, majoring in B.A. Education. He also received an MBA degree from Washington University, MO USA in 1999.

Pursuant to the letter of appointment entered into between the Company and Mr. Shimada, he has been appointed for a term of two years commencing from 1 November 2023 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Mr. Shimada is entitled to a monthly salary of JPY282,000 on a 13-month basis and a year-end discretionary bonus, which has been recommended by the remuneration committee of the Board and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

Mr. Miyazato, aged 58, started his early career in Credit Suisse (CSFB), and JP Morgan as an investment banker, and then joined Nikko (Citigroup) Asset Management as a fund manager where he created the cross-border arbitrage hedge fund and China-focus pilot fund. Mr. Miyazato has built a senior management career in Haitong Securities group as a deputy chief executive officer, responsible for investment and overseas business development and he also worked as the chairman of the executive board and a chief executive officer for Haitong Bank where he built his international practice.

Mr. Miyazato founded Sunrise Oriental Japan LLC which aims at connecting China and Japan, as well as the rest of Asia regarding to the cross-border corporate interactions and had even served as the vice chairman of the OTC Business Committee of the Securities Association of China and the vice chairman of the Shanghai Cross-border Business Committee.

Mr. Miyazato graduated from Fudan University in Shanghai majoring in genetics. He also received his second degree from Tokyo University in Tokyo majoring in biophysics and biochemistry.

Pursuant to the letter of appointment entered into between the Company and Mr. Miyazato, he has been appointed for a term of two years commencing from 1 November 2023 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Mr. Miyazato is entitled to a monthly salary of JPY85,000 on a 13-month basis and a year-end discretionary bonus, which has been recommended by the remuneration committee of the Board and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

Mr. Chiu, aged 59, has been appointed as the company secretary of the Company, a LR Authorised Representative and a CO Authorised Representative since 30 June 2021. He has over 37 years of experience in overseeing accounting, auditing, corporate finance, merger and acquisition, taxation and company secretarial business. He is a Hong Kong practicing Certified Public Accountants and a fellow member of Hong Kong Institute of Certified Public Accountants. Prior to joining the Group, Mr. Chiu has been the founder of C.T. Chiu & Co., CPA and has also worked in a multinational company. Mr. Chiu graduated from the Hong Kong Polytechnic University majoring in accounting. Mr. Chiu is also a director of a subsidiary of the Company.

Pursuant to the letter of appointment entered into between the Company and Mr. Chiu, he has been appointed for a term of two years commencing from 1 November 2023 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Mr. Chiu is entitled to a monthly salary of HKD90,000 on a 13-month basis and a year-end discretionary bonus, which has been recommended by the remuneration committee of the Board and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

Non-executive Directors

Mr. Kusaba, aged 47, joined EPS Japan, a controlling shareholder (as defined under the Listing Rules) of the Company, in March 2022 and was appointed as the Head of Investment Management Office and the Deputy Head of Corporate & Alliance Planning Office in October 2022, where he is responsible for business development and alliances as well as investment management within the group. Mr. Kusaba joined Mitsubishi Corporation in 2000, and he has been involved in numerous business development, business investment, and alliances in Japan and overseas, mainly focusing in telecom, IT services, and retail industries. When stationed in the United States from 2010 to 2015, he served as the executive vice president of a subsidiary of Mitsubishi Corporation, which offers enterprise IT services, and he was responsible for corporate planning, marketing, and sales. Mr. Kusaba is a colleague of Mr. Miyano, Mr. Hari, Mr. Maezaki, the existing executive Directors and Mr. Shimada, a newly appointed executive Director, in EPS Japan.

Mr. Kusaba completed a Master's Degree of Engineering from Kyoto University. Additionally, he received an MBA degree in Finance from Hitotsubashi University.

Pursuant to the letter of appointment entered into between the Company and Mr. Kusaba, he has been appointed for a term of two years commencing from 1 November 2023 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Mr. Kusaba is entitled to a monthly salary of JPY85,000 on a 12-month basis, which has been recommended by the remuneration committee of the Board and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

Mr. Yan, aged 59, is a businessman and has extensive experience in biomedical industry in the People's Republic of China. Mr. Yan was the chairman of the board of directors and the general manager of 益通(蘇州)醫療技術有限公司 from 2013 to 2017 and was as the chairman of the board of directors of 益新(中國)有限公司 during 2018 to 2020, and since 2022 and has been the chairman of the board of directors of 上海華新生物高技術有限公司 since 2021. Mr. Yan graduated from Wuxi Institute of Light Industry (無錫輕工業學院) (now known as Jiangnan University (江南大學)) in 1984. Mr. Yan is the brother of Mr. Yan Hao, who indirectly owns as to 71.51% of EPS Japan being a controlling shareholder (as defined under the Listing Rules) of the Company.

Pursuant to the letter of appointment entered into between the Company and Mr. Yan, he has been appointed for a term of two years commencing from 1 November 2023 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Mr. Yan is entitled to a monthly salary of HKD5,000 on a 12-month basis, which has been recommended by the remuneration committee of the Board and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

Independent non-executive Director

Mr. Saito, aged 61, has been working in Daiichi Sankyo Company, Limited (“**Daiichi Sankyo**”), a Japanese pharmaceutical company the shares of which are listed on the Japanese (Tokyo) Stock Exchange (ticker code: 4586), for almost 34 years. He moved to the clinical strategic team and became the team leader of anti-hypertensive agents named Olmesartan in Japan from 1997 to 2005 and became a senior vice director to register Olmesartan in the rest of world (Asia, South and Central America and Saudi Arabia etc.). From 2012, he has been the vice president of the new drug regulatory affairs department in Japan and the co-chairman of the Global Regulatory Affairs Committee. He has been the vice president of oncology clinical development in Japan from April 2016. From April 2023, he has been the Corporate Advisor of Daiichi Sankyo.

Mr. Saito has been the president of SAITO Concierge Co., Ltd from September 2023. Mr. Saito received his Ph.D. from Chiba University in Japan. He is also the vice chairperson of the ICH Steering Committee of the Japan Pharmaceutical Manufacturers Association (JPMA).

Pursuant to the letter of appointment entered into between the Company and Mr. Saito, he has been appointed for a term of two years commencing from 1 November 2023 and is subject to the provision of retirement by rotation and re-election at the annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. According to the terms of the letter of appointment, Mr. Saito is entitled to a monthly salary of HKD10,000 on a 12-month basis, which has been recommended by the remuneration committee of the Board and approved by the Board with reference to his qualifications, experience and responsibilities with the Company.

As at the date of this announcement, save as disclosed above, each of Mr. Shimada, Mr. Miyazato, Mr. Chiu, Mr. Kusaba, Mr. Yan and Mr. Saito (i) does not hold any other position with the Company or any of its subsidiaries; (ii) has not held any other directorship in, or direct or indirect interest in 10% or more of the issued share capital of, any other public companies the securities of which are listed on any security market in Hong Kong or overseas in the three years prior to the date of this announcement; (iii) does not have any other relationship with any directors, senior management or substantial or controlling shareholders (as defined under the Listing Rules) of the Company; and (iv) does not have any interest in the shares or underlying shares in the Company (within the meaning of Part XV of the SFO).

Save as disclosed above, there is no information in relation to the appointments of Mr. Shimada, Mr. Miyazato, Mr. Chiu, Mr. Kusaba, Mr. Yan and Mr. Saito as Directors that is required to be disclosed pursuant to any of the requirements under paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules, and there is no other matter that needs to be brought to the attention of the Shareholders.

CHANGE OF AUTHORISED REPRESENTATIVE

Following the resignation of Mr. Gao with effect from 1 November 2023, Mr. Miyano, now an executive Director, has been appointed as a LR Authorised Representative.

CHANGE IN COMPOSITION OF THE AUDIT COMMITTEE

Mr. Xia has resigned as a member of the Audit Committee and Mr. Kusaba has been appointed as a member of the Audit Committee, all with effect from 1 November 2023.

The Board would like to extend its warm welcome to Mr. Shimada, Mr. Miyazato, Mr. Chiu, Mr. Kusaba, Mr. Yan and Mr. Saito on their respective appointments.

CHANGE OF DIRECTORS' FUNCTIONS

With effect from 1 November 2023, the role of each of (i) Mr. Hari, now an executive Director, has been changed from the chief financial officer of the Company (the “**Chief Financial Officer**”) to the chief accounting officer of the Company (the “**Chief Accounting Officer**”); and (ii) Mr. Maezaki, now an executive Director, has been changed from the chief management officer of the Company (the “**Chief Management Officer**”) to the Chief Financial Officer.

By order of the Board
EPS Creative Health Technology Group Limited
Miyano Tsumoru
Executive Director

Hong Kong, 1 November 2023

As at the date of this announcement, the executive Directors are Mr. Shimada Tatsuji, Mr. Miyano Tsumoru, Mr. Maezaki Masahiro, Mr. Haribayashi Keikyo, Mr. Miyazato Hiroki and Mr. Chiu Chun Tak; the non-executive Directors are Mr. Kusaba Takuya and Mr. Yan Ping; and the independent non-executive Directors are Mr. Chan Cheuk Ho, Mr. Taguchi Junichi, Mr. Choi Koon Ming and Mr. Saito Hironobu.